Influenza immunization (DBCOND0025221)

Identifiers

Synonyms

Flu prophylaxis / Flu vaccination / Influenza immunisation / Flu prevention / Administration of vaccine product containing only Influenza virus antigen (procedure)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06361875	A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B (Victoria-like) Haemagglutinin-strain B (Yamagata-like) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen	prevention	1 / 2	active_not_recruiting
NCT05650554	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B (Victoria-like) Haemagglutinin-strain B (Yamagata-like) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen	prevention	1 / 2	completed
NCT06118151	Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older	Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen	prevention	1	completed
NCT04551677	Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B (Victoria-like) Haemagglutinin-strain B (Yamagata-like) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated)	other	4	completed
NCT05829356	Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above	Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen	prevention	1	completed
NCT05050318	Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B (Victoria-like) Haemagglutinin-strain B (Yamagata-like) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated)	other	4	completed
NCT05426174	Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)	prevention	1	completed
NCT04969276	Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine	Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Moderna COVID-19 Vaccine	prevention	2	completed
NCT05513391	Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years	Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Brisbane/59/2007 (H1N1) hemagglutinin antigen (formaldehyde inactivated) Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza A virus A/South Australia/34/2019 IVR-197 (H3N2) antigen (formaldehyde inactivated) Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (formaldehyde inactivated) Influenza A virus subtype H1N1 haemagglutinin, recombinant Influenza A virus subtype H3N2 haemagglutinin, recombinant Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Phuket/3073/2013 live (attenuated) antigen Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen Influenza B virus Victoria lineage haemagglutinin, recombinant Influenza B virus Yamagata lineage haemagglutinin, recombinant	prevention	3	terminated
NCT05513053	Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.	Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza A virus subtype H1N1 haemagglutinin, recombinant Influenza A virus subtype H3N2 haemagglutinin, recombinant Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen Influenza B virus Victoria lineage haemagglutinin, recombinant Influenza B virus Yamagata lineage haemagglutinin, recombinant	prevention	3	completed
NCT04024228	Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B	prevention	3	completed
NCT04498832	Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older	No drug interventions	treatment	3	completed
NCT05624606	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B (Victoria-like) Haemagglutinin-strain B (Yamagata-like) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Massachusetts/2/2012 BX-51B antigen (formaldehyde inactivated) Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen	prevention	1 / 2	completed
NCT05553301	Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older	Haemagglutinin-strain A(H1N1) Haemagglutinin-strain A(H3N2) Haemagglutinin-strain B (Victoria-like) Haemagglutinin-strain B (Yamagata-like) Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen Influenza A virus A/Michigan/45/2015 (H1N1) recombinant hemagglutinin antigen Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) Influenza B virus B/Brisbane/60/2008 recombinant hemagglutinin antigen Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen	prevention	1 / 2	completed